Investigational drug · Phase 3
AZD5335
Also called: Torvutatug samrotecan, Torvu-sam
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Epithelial Ovarian Cancer, Ovarian Cancer, Lung Adenocarcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
5
Any phase or sponsor naming "AZD5335"
First trial start
2023
Jun 5, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AZD5335", any sponsor or status.
Conditions studied
As listed on its trial records.
- Epithelial Ovarian Cancer
- Ovarian Cancer
- Lung Adenocarcinoma
- Endometrial Cancer
- Lung Squamous Cell Carcinoma
- Platinum-sensitive Relapsed Epithelial Ovarian Cancer
- Platinum-sensitive Relapsed Fallopian Tube Cancer
- Platinum-sensitive Relapsed Primary Peritoneal Cancer
Approved drugs for the same conditions: Ovarian cancer · Endometrial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "AZD5335" as an intervention, largest first.
- AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07218809 · 1,100 participants (planned) · Start Dec 29, 2025 · Primary completion Nov 17, 2028
Drug: AZD5335; Mirvetuximab Soravtansine (MIRV) and 3 more · For: Epithelial Ovarian Cancer
Sites: Birmingham, Alabama; Little Rock, Arkansas; La Jolla, California · 299 sites in all
- Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07851025 · 950 participants (planned) · Start Sep 16, 2026 · Primary completion Jun 28, 2030
Drug: Torvutatug samrotecan; Bevacizumab · For: Epithelial Ovarian Cancer
Sites: Tamarac, Florida; Tampa, Florida; Baton Rouge, Louisiana · 220 sites in all
- Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05797168 · 622 participants (planned) · Start Jun 5, 2023 · Primary completion Aug 4, 2028
Drug: Torvutatug samrotecan; Saruparib and 4 more · For: Ovarian Cancer; Lung Adenocarcinoma; Endometrial Cancer and 1 more
Sites: Duarte, California; Irvine, California; La Jolla, California · 60 sites in all
- Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian CancerPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07816666 · 600 participants (planned) · Start Sep 24, 2026 · Primary completion Sep 29, 2028
Drug: Torvutatug samrotecan; Bevacizumab · For: Platinum-sensitive Relapsed Epithelial Ovarian Cancer; Platinum-sensitive Relapsed Fallopian Tube Cancer; Platinum-sensitive Relapsed Primary Peritoneal Cancer
Sites: Anchorage, Alaska; Miami, Florida; Indianapolis, Indiana · 124 sites in all
AstraZenecaAstraZeneca (AZN)
NCT07402915 · 32 participants (planned) · Start Jan 26, 2026 · Primary completion Oct 15, 2027
Drug: AZD5335; Itraconazole · For: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal
Sites: Batumi, Georgia; Tbilisi, Georgia; Dublin, Ireland · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Targeting Folate Receptors for the Detection and Selective Treatment of Cancer: Advanced Precision Oncology in Practice.
Stark M, Assaraf YG · Int J Biol Sci 2026
- Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers.
Zoeller JJ, Tammali R, Dodd RB, et al. · Clin Cancer Res 2025
Also in development for Epithelial Ovarian Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- IMNN-001IL-12 Plasmid with PEG-PEI-Cholesterol Lipopolymer, GEN-1Phase 33 trials
Imunon · Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer
- RC88The RC88Phase 23 trials
RemeGen Co., Ltd. · Solid Tumor, Advanced Solid Tumours, Primary Peritoneal Cancer
- AVZO-021Phase 22 trials
Avenzo Therapeutics, Inc. · HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer, Advanced Solid Tumor
- Dual-target CAR-NK cell productPhase 22 trials
Beijing Biotech · Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma
- CBX-12Phase 21 trial
Cybrexa Therapeutics · Solid Tumor, Adult, Epithelial Ovarian Cancer, Small Cell Lung Carcinoma
- ETX-19477Phase 21 trial
858 Therapeutics, Inc. · Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer
- KAND567FractalkinePhase 21 trial
Novakand Pharma AB · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.